Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Reports Full-Year 2013 Financial Results
Management to Host Conference Call and Audio Webcast Today at 4:30 p.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the year ended December 31, 2013 . "2013 was a productive and eventful year for Retrophin," said Martin Shkreli , Founder
View HTML
Toggle Summary Retrophin Completes Acquisition of Manchester Pharmaceuticals
Transaction Transforms Retrophin into a Commercial Company with Two FDA-Approved Products Company Plans to Pursue Approval of Chenodal in CTX NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced the completion of the previously announced acquisition of Manchester
View HTML
Toggle Summary Retrophin Announces Agreement to Acquire Manchester Pharmaceuticals
Acquisition Brings Two FDA-Approved Products Management to Host Conference Call and Webcast Tomorrow at 8:30 a.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has signed an agreement to acquire Manchester Pharmaceuticals® LLC, a privately-held
View HTML
Toggle Summary Retrophin to Present at the 16th Annual BIO CEO & Investor Conference
Corporate update to be given February 11 at 9 a.m. EST NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced that Founder and CEO Martin Shkreli will present a corporate overview and update at the 16 th Annual BIO CEO & Investor Conference being held February 10-11 in New York
View HTML
Toggle Summary Retrophin Announces Pricing of Public Offering of Common Shares
Uplisted to NASDAQ Global Market Under Symbol "RTRX" NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX)(formerly OTCQB:RTRX) today announced the pricing of an underwritten public offering of 4,705,882 shares of its common stock, offered at a price of $8.50 per share.
View HTML
Toggle Summary Retrophin Announces Public Offering of Common Stock
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has commenced an offering to sell $40,000,000 of shares of its common stock in a proposed underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to
View HTML
Toggle Summary Retrophin Unveils New Clinical Development Candidate RE-034, An ACTH Analog
Company to Initiate Clinical Development in Multiple Indications Management to Host Conference Call and Webcast Tomorrow at 9:00 a.m. ET NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced its newest clinical development candidate RE-034 (cosyntropin), a long-acting synthetic
View HTML
Toggle Summary Retrophin Withdraws Offer for Transcept Pharmaceuticals
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has withdrawn its offer to acquire all of the shares of Transcept Pharmaceuticals, Inc.'s common stock for $4.00 per share in cash. Retrophin is no longer a shareholder of Transcept.
View HTML
Toggle Summary Retrophin Announces Agreement to Acquire Kyalin Biosciences
Acquisition expands Retrophin's CNS Pipeline NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it will acquire privately-held Kyalin Biosciences, Inc. , an early-stage company based in San Diego, CA , that is developing therapies targeting the core symptoms of autism
View HTML
Toggle Summary Retrophin to Co-Sponsor Clinical Trial of Intranasal Oxytocin for Schizophrenia
  Data will support company's clinical development program of Syntocinon ™ for the treatment of schizophrenia NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) announced that it has agreed to support Phase II clinical trial of oxytocin for the treatment of schizophrenia
View HTML